First results with PD-1 or/and CTLA-4 blockade indicate best responses in relapsed HD, but also other hematological malignancies, such as acute leukemia and NHL, show adequate responses to CI after allo-HCT. Here, CTLA4 is linked to non-Hodgkin lymphoma.